NCK1-DT: A Potential Drug Target for various Diseases (G101927597)

Target Name: NCK1-DT

NCBI ID: G101927597

NCK1-DT

Other Name(s): NCK1-AS1 | SLC35G2-AS1 | NCK1 divergent transcript | NCK1-DT variant 1 | NCK1 divergent transcript, transcript variant 1

NCK1-DT: A Potential Drug Target for various Diseases

NCK1-DT, also known as NCK1-AS1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a key regulator of the calcium ions in these tissues, and plays a crucial role in their function and development.

Recent studies have identified NCK1-DT as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This is because the disruption of NCK1-DT has been linked to the development and progression of these conditions.

One of the key reasons for the potential of NCK1-DT as a drug target is its involvement in several cellular processes that are important for human health. For example, NCK1-DT has been shown to regulate the activity of muscles, which is essential for movement and maintaining posture. It also plays a role in the development and maintenance of the blood-brain barrier, which is important for the exchange of nutrients and oxygen to the brain.

In addition to its role in cellular processes, NCK1-DT has also been shown to be involved in several signaling pathways that are important for human health. For example, it has been shown to play a role in the regulation of cell growth, apoptosis (programmed cell death), and inflammation.

The potential benefits of targeting NCK1-DT as a drug target are significant. If successful, these treatments could be used to treat a wide range of conditions, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, in cancer, targeting NCK1-DT has been shown to inhibit the growth and spread of cancer cells. In neurodegenerative diseases, targeting NCK1-DT has been shown to slow the progression of neurodegeneration and improve symptoms. In cardiovascular diseases, targeting NCK1-DT has been shown to improve blood flow and reduce the risk of cardiovascular events.

The development of small molecules that can specifically target NCK1-DT is an exciting area of research. These molecules could be used to treat a wide range of conditions, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, one small molecule that has been shown to be a potential NCK1-DT inhibitor is called NX1-485. In clinical trials, NX1-485 has been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, NCK1-DT is a protein that plays a crucial role in various cellular processes that are important for human health. The potential of targeting NCK1-DT as a drug target for various diseases is significant, and the development of small molecules that can specifically target NCK1-DT is an exciting area of research. Further studies are needed to determine the effectiveness of these treatments and to develop safe and effective therapies.

Protein Name: NCK1 Divergent Transcript

The "NCK1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCK1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets